VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
NHC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
NHCNational HealthCare Corporation
$225.01$3.5B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. NHC
  4. Financial Ratios

National HealthCare Corporation (NHC) Financial Ratios

Latest Ratios: P/E Ratio 29.3x · EV/EBITDA 20.1x · ROE 11.7%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

NHC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$3.5B$2.1B$1.7B$1.4B$919M$1.0B$1.0B$1.3B$1.2B$927M$1.2B
Enterprise Value$3.5B$2.1B$1.8B$1.4B$986M$1.1B$1.1B$1.5B$1.1B$856M$1.3B
P/E Ratio →29.3417.8716.4721.2941.037.5624.4219.4720.2716.5122.83
P/S Ratio2.321.411.291.240.861.041.041.331.220.961.25
P/B Ratio3.282.001.711.561.051.151.281.701.631.321.83
P/FCF23.6514.4321.0517.06—45.555.6318.0117.4114.9340.75
P/OCF18.9911.5915.6412.78105.1416.795.0213.2612.149.8212.68

P/E links to full P/E history page with 30-year chart

NHC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.401.401.230.921.091.091.511.110.891.38
EV / EBITDA20.1512.2414.2214.1913.6312.0811.8416.5011.128.8512.82
EV / EBIT27.2012.5712.9215.8035.497.3319.8416.5613.7010.7815.17
EV / FCF—14.2722.7916.89—48.125.8920.4815.8713.7845.13

NHC Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin39.3%39.3%37.5%37.6%36.1%34.1%37.9%40.5%40.6%40.7%40.7%
Operating Margin8.5%8.5%6.6%5.0%3.0%5.0%4.9%4.9%5.7%5.6%6.6%
Net Profit Margin7.9%7.9%7.9%5.9%2.1%13.7%4.3%6.8%6.0%5.8%5.5%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE11.7%11.7%10.8%7.5%2.5%16.2%5.3%9.0%8.2%8.4%8.0%
ROA7.9%7.9%7.2%5.2%1.7%10.0%3.2%5.8%5.4%5.1%4.7%
ROIC8.9%8.9%6.4%4.7%2.5%4.2%4.0%4.6%6.7%5.9%6.1%
ROCE10.0%10.0%7.2%5.3%2.9%4.6%4.4%4.9%6.0%5.8%6.6%

NHC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.080.080.220.100.140.180.240.300.110.180.24
Debt / EBITDA0.500.501.680.941.741.822.152.540.801.311.51
Net Debt / Equity—-0.020.14-0.020.080.060.060.23-0.14-0.100.20
Net Debt / EBITDA-0.14-0.141.09-0.140.930.640.521.99-1.08-0.741.24
Debt / FCF—-0.161.74-0.16—2.570.262.47-1.54-1.154.38
Interest Coverage26.5026.5033.99274.8849.37178.5638.4729.0716.9416.2521.35

Net cash position: cash ($111M) exceeds total debt ($87M)

NHC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.771.771.811.891.791.621.621.752.042.121.93
Quick Ratio1.771.771.771.861.751.591.591.711.992.081.88
Cash Ratio1.221.220.921.040.920.971.151.041.161.281.26
Asset Turnover—0.990.850.870.840.720.720.770.910.880.85
Inventory Turnover——89.7196.4596.8177.6169.3979.6778.0179.9772.99
Days Sales Outstanding—33.4338.2034.8734.0734.8733.3733.4536.7035.4731.91

NHC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield1.1%1.8%2.2%2.5%3.8%3.1%3.1%2.4%2.5%3.0%2.2%
Payout Ratio32.2%32.2%36.3%53.2%154.2%23.1%76.2%45.8%50.6%50.2%51.0%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield3.4%5.6%6.1%4.7%2.4%13.2%4.1%5.1%4.9%6.1%4.4%
FCF Yield4.2%6.9%4.8%5.9%—2.2%17.8%5.6%5.7%6.7%2.5%
Buyback Yield0.4%0.7%0.8%0.2%1.1%0.1%0.0%0.1%0.1%0.0%0.7%
Total Shareholder Yield1.5%2.5%3.0%2.7%4.8%3.1%3.1%2.4%2.6%3.0%2.9%
Shares Outstanding—$16M$16M$15M$15M$15M$15M$15M$15M$15M$15M

Key Metrics

Growth RegimeAccelerating
ProfitabilityStable
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Regulatory staffing mandate risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Premium Pricing for Real Estate Backing

NHC trades at 29.2x trailing earnings and 20.0x EV/EBITDA, a premium to peers like EHC (22.3x P/E, 10.8x EV/EBITDA), reflecting its owned real estate and fortress balance sheet, per reported multiples.

The forward EV/EBITDA of 10.3x suggests the market expects significant EBITDA growth, likely from margin recovery and behavioral health expansion. However, the P/E premium may be justified by the hidden value of owned properties, which are not reflected in book value. Investors should monitor whether earnings growth materializes to support the current multiple.

Margin Recovery Masks Investment Noise

Gross margin improved to 40.7% in 2026Q2 from 36.6% a year earlier, while operating margin rose to 12.0%, as per financial statements, indicating operational discipline despite labor cost pressures.

Net margin of 9.9% in 2026Q2 is flattered by non-operating investment gains, which are volatile and not indicative of core operations. Normalized operating margin of 12.0% is more representative of earning power, but it remains below pre-pandemic levels. The stability of gross margin suggests cost management is effective, yet labor inflation and potential staffing mandates could erode this.

Returns Compress Despite Deleveraging

ROIC improved to 3.4% in 2026Q2 from 1.3% in 2024Q1, but remains low relative to peers like EHC (13.9%), as reported, reflecting the heavy asset base from owned real estate.

The low ROIC is a direct consequence of the owner-operator model, where significant capital is tied up in properties. While this provides a fortress balance sheet, it depresses returns on capital compared to asset-light peers. The recent improvement is driven by margin expansion and revenue growth, but the absolute level suggests the market may be valuing the real estate rather than operational returns.

Working Capital Efficiency Improves

DSO fell to 31 days in 2026Q2 from 37 days in 2024Q2, while CCC remained negative at -8 days, as per reported figures, indicating efficient receivables collection and favorable payment terms.

The negative cash conversion cycle is a positive sign, as NHC collects from payers before paying suppliers, reducing the need for working capital financing. However, the DPO of 8 days is unusually low, suggesting NHC pays suppliers quickly, possibly to maintain relationships. Asset turnover of 0.27x is low due to the heavy real estate base, but this is structural and not a sign of operational inefficiency.

Negligible Debt Provides Strategic Flexibility

Debt-to-equity fell to 0.03 in 2026Q2 from 0.22 in 2024Q4, with interest coverage exceeding 4,000x, as per balance sheet data, indicating minimal financial risk and ample borrowing capacity.

The rapid deleveraging from $214.8M to $31.4M in total debt over six quarters reflects strong cash generation and conservative capital allocation. This fortress balance sheet allows NHC to pursue acquisitions or weather regulatory shocks without refinancing risk. However, the low leverage may also signal a lack of aggressive growth initiatives, which could limit upside.

Liquidity Buffer Reaches Exceptional Levels

Current ratio surged to 22.06 in 2026Q2 from 1.77 a year earlier, with cash at $51.1M, as reported, indicating an extraordinarily strong short-term liquidity position.

The spike in the current ratio is driven by a significant increase in current assets, likely from marketable securities and cash. This provides a substantial cushion against operational disruptions or unexpected liabilities. However, such high liquidity may be inefficient, as excess cash could be deployed for higher returns. The quick ratio of 22.06 confirms that inventory is not a concern, given the service-based nature of the business.

Balance Sheet Strength vs. Operational Returns

NHC's D/E of 0.03 is far below peers like EHC (0.83) and PNTG (1.21), but its ROE of 3.6% lags EHC's 18.7%, as per reported data, highlighting a trade-off between safety and returns.

The peer comparison reveals a clear divergence: NHC's fortress balance sheet and owned real estate provide stability, but its returns on equity and capital are significantly lower than asset-light operators. This suggests the market may be pricing NHC as a real estate play rather than a high-growth healthcare provider. The gap in ROE is structural, not temporary, and investors should weigh the safety of the balance sheet against the lower operational returns.

Misapplied ROIC in Asset-Heavy Model

ROIC is commonly misapplied to NHC because it penalizes the company for owning real estate, which is a strategic advantage, as per reported figures, obscuring true economic returns.

Standard ROIC calculations treat owned properties as invested capital, but these assets generate rental savings and appreciation that are not captured in operating income. A more appropriate metric would be ROIC adjusted for the capitalized value of operating leases, or EV/EBITDAR, which levels the playing field with asset-light peers. Investors should focus on cash-on-cash returns from operations and the potential for real estate monetization, rather than raw ROIC.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open NHC Terminal

NHC Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

NHC — Frequently Asked Questions

Quick answers to the most common questions about buying NHC stock.

What is National HealthCare Corporation's P/E ratio?

National HealthCare Corporation's current P/E ratio is 29.3x. The historical average is 21.5x. This places it at the 93th percentile of its historical range.

What is National HealthCare Corporation's EV/EBITDA?

National HealthCare Corporation's current EV/EBITDA is 20.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.1x.

What is National HealthCare Corporation's ROE?

National HealthCare Corporation's return on equity (ROE) is 11.7%. The historical average is 11.6%.

Is NHC stock overvalued?

Based on historical data, National HealthCare Corporation is trading at a P/E of 29.3x. This is at the 93th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is National HealthCare Corporation's dividend yield?

National HealthCare Corporation's current dividend yield is 1.10% with a payout ratio of 32.2%.

What are National HealthCare Corporation's profit margins?

National HealthCare Corporation has 39.3% gross margin and 8.5% operating margin.

How much debt does National HealthCare Corporation have?

National HealthCare Corporation's Debt/EBITDA ratio is 0.5x, indicating low leverage. A ratio below 2x is generally considered financially healthy.